Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. [electronic resource]
Producer: 20190919Description: 2837-2847 p. digitalISSN:- 2473-9537
- Adult
- Aged
- Bone Density
- Bone Density Conservation Agents -- adverse effects
- Bone Remodeling
- Collagen Type I -- metabolism
- Denosumab -- adverse effects
- Double-Blind Method
- Drug Administration Schedule
- Female
- Headache -- etiology
- Humans
- Male
- Middle Aged
- Osteoporosis -- drug therapy
- Osteoprotegerin -- metabolism
- Peptides -- metabolism
- Placebo Effect
- RANK Ligand -- metabolism
- Thalassemia -- complications
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.